MX2021015538A - Metodo para la generacion de una celula que expresa un anticuerpo biespecifico bivalente mediante la integracion dirigida de multiples casetes de expresion en una organizacion definida. - Google Patents
Metodo para la generacion de una celula que expresa un anticuerpo biespecifico bivalente mediante la integracion dirigida de multiples casetes de expresion en una organizacion definida.Info
- Publication number
- MX2021015538A MX2021015538A MX2021015538A MX2021015538A MX2021015538A MX 2021015538 A MX2021015538 A MX 2021015538A MX 2021015538 A MX2021015538 A MX 2021015538A MX 2021015538 A MX2021015538 A MX 2021015538A MX 2021015538 A MX2021015538 A MX 2021015538A
- Authority
- MX
- Mexico
- Prior art keywords
- domain
- heavy chain
- light chain
- bivalent
- expression cassette
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
- C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
- C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0684—Cells of the urinary tract or kidneys
- C12N5/0686—Kidney cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/66—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a swap of domains, e.g. CH3-CH2, VH-CL or VL-CH1
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
- C12N2510/02—Cells for production
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/106—Plasmid DNA for vertebrates
- C12N2800/107—Plasmid DNA for vertebrates for mammalian
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT
Abstract
En el presente documento se informa un método para producir un anticuerpo biespecífico bivalente que comprende las etapas de cultivar una célula de mamífero que comprende un ácido desoxirribonucleico que codifica el anticuerpo biespecífico bivalente, y recuperar el anticuerpo biespecífico bivalente de la célula o el medio de cultivo, en el que el ácido desoxirribonucleico que codifica el anticuerpo biespecífico bivalente se integra establemente en el genoma de la célula de mamífero y comprende en la dirección 5' a 3' ya sea un primer casete de expresión que codifica la primera cadena ligera, un segundo casete de expresión que codifica la primera cadena pesada, un tercer casete de expresión que codifica la segunda cadena ligera, y un cuarto casete de expresión que codifica la segunda cadena pesada, o un primer casete de expresión que codifica la primera cadena ligera, un segundo casete de expresión que codifica la segunda cadena pesada, un tercer casete de expresión que codifica la segunda cadena ligera, y un cuarto casete de expresión que codifica la primera cadena pesada, en el que la primera cadena pesada comprende desde el extremo N- al C-terminal un primer dominio variable de la cadena pesada, un dominio CH1, una región bisagra, un dominio CH2 y un dominio CH3, la segunda cadena pesada comprende desde el extremo N- al C-terminal el primer dominio variable de la cadena ligera, un dominio CH1, una región bisagra, un dominio CH2 y un dominio CH3, la primera cadena ligera comprende desde el extremo N- al C-terminal terminal un segundo dominio variable de la cadena pesada y un dominio CL, y la segunda cadena ligera comprende desde el extremo N- al C-terminal un segundo dominio de la cadena ligera y un dominio CL, en el que el primer dominio variable de la cadena pesada y el segundo dominio variable de la cadena ligera forman un primer sitio de unión y el segundo dominio variable de la cadena pesada y el primer dominio variable de la cadena ligera forman un segundo sitio de unión.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19181097 | 2019-06-19 | ||
| PCT/EP2020/066685 WO2020254355A1 (en) | 2019-06-19 | 2020-06-17 | Method for the generation of a bivalent, bispecific antibody expressing cell by targeted integration of multiple expression cassettes in a defined organization |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021015538A true MX2021015538A (es) | 2022-02-10 |
Family
ID=67060257
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021015538A MX2021015538A (es) | 2019-06-19 | 2020-06-17 | Metodo para la generacion de una celula que expresa un anticuerpo biespecifico bivalente mediante la integracion dirigida de multiples casetes de expresion en una organizacion definida. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20220169730A1 (es) |
| EP (1) | EP3986926A1 (es) |
| JP (2) | JP2022537338A (es) |
| KR (1) | KR20220010019A (es) |
| CN (1) | CN114008081A (es) |
| AU (1) | AU2020294879A1 (es) |
| BR (1) | BR112021025462A2 (es) |
| CA (1) | CA3140318A1 (es) |
| IL (1) | IL288967A (es) |
| MX (1) | MX2021015538A (es) |
| WO (1) | WO2020254355A1 (es) |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| EP0307434B2 (en) | 1987-03-18 | 1998-07-29 | Scotgen Biopharmaceuticals, Inc. | Altered antibodies |
| ATE159548T1 (de) | 1990-11-13 | 1997-11-15 | Immunex Corp | Bifunktionelle wählbare fusionsgene |
| WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
| CA2163427A1 (en) | 1993-05-21 | 1994-12-08 | Stephen D. Lupton | Bifunctional selectable fusion genes based on the cytosine deaminase (cd) gene |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| IL151853A0 (en) | 2000-04-11 | 2003-04-10 | Genentech Inc | Multivalent antibodies and uses therefor |
| EA014182B1 (ru) | 2004-07-20 | 2010-10-29 | Симфоген А/С | КОМПОЗИЦИЯ ПОЛИКЛОНАЛЬНЫХ АНТИ-RhD АНТИТЕЛ, СПОСОБ ЕЁ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЕ КОМПОЗИЦИИ |
| US9266967B2 (en) | 2007-12-21 | 2016-02-23 | Hoffmann-La Roche, Inc. | Bivalent, bispecific antibodies |
| US8242247B2 (en) | 2007-12-21 | 2012-08-14 | Hoffmann-La Roche Inc. | Bivalent, bispecific antibodies |
| US8227577B2 (en) | 2007-12-21 | 2012-07-24 | Hoffman-La Roche Inc. | Bivalent, bispecific antibodies |
| US20090162359A1 (en) * | 2007-12-21 | 2009-06-25 | Christian Klein | Bivalent, bispecific antibodies |
| PL2235064T3 (pl) | 2008-01-07 | 2016-06-30 | Amgen Inc | Sposób otrzymywania cząsteczek przeciwciał z heterodimerycznymi fc z zastosowaniem kierujących efektów elektrostatycznych |
| US8268314B2 (en) | 2008-10-08 | 2012-09-18 | Hoffmann-La Roche Inc. | Bispecific anti-VEGF/anti-ANG-2 antibodies |
| CA2756244A1 (en) | 2009-04-02 | 2010-10-07 | Roche Glycart Ag | Multispecific antibodies comprising full length antibodies and single chain fab fragments |
| CA2757931C (en) | 2009-04-07 | 2019-03-26 | Roche Glycart Ag | Trivalent, bispecific antibodies |
| BRPI1007602A2 (pt) | 2009-05-27 | 2016-02-16 | Hoffmann La Roche | "anticorpo tri ou tetraespecífico, método para preparação de um anticorpo triespecífico ou tetraespecífico, célula hospedeira, composição, composição farmacêutica e método para o tratamento de um paciente com necessidade de terapia" |
| US9676845B2 (en) | 2009-06-16 | 2017-06-13 | Hoffmann-La Roche, Inc. | Bispecific antigen binding proteins |
| US8703132B2 (en) | 2009-06-18 | 2014-04-22 | Hoffmann-La Roche, Inc. | Bispecific, tetravalent antigen binding proteins |
| TWI426920B (zh) | 2010-03-26 | 2014-02-21 | Hoffmann La Roche | 雙專一性、雙價抗－ｖｅｇｆ／抗－ａｎｇ－２抗體 |
| EP2726510B1 (en) | 2011-05-27 | 2023-03-08 | F. Hoffmann-La Roche AG | Dual targeting |
| WO2013006142A1 (en) | 2011-07-05 | 2013-01-10 | Nanyang Technological University | A novel process and reagent for rapid genetic alterations in eukaryotic cells |
| MY183712A (en) | 2012-07-13 | 2021-03-09 | Roche Glycart Ag | Bispecific anti-vegf/anti-ang-2 antibodies and their use in the treatment of ocular vascular diseases |
| HUE055407T2 (hu) | 2015-10-02 | 2021-11-29 | Hoffmann La Roche | PD1-re és TIM3-ra specifikus bispecifikus antitestek |
| US11530277B2 (en) * | 2016-04-20 | 2022-12-20 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for making antibodies based on use of an expression-enhancing locus |
| CN110402253B (zh) | 2017-03-10 | 2024-01-05 | 豪夫迈·罗氏有限公司 | 用于生产多特异性抗体的方法 |
| TWI690538B (zh) | 2017-04-05 | 2020-04-11 | 瑞士商赫孚孟拉羅股份公司 | 特異性結合至pd1至lag3的雙特異性抗體 |
-
2020
- 2020-06-17 EP EP20734132.2A patent/EP3986926A1/en active Pending
- 2020-06-17 CN CN202080044539.0A patent/CN114008081A/zh active Pending
- 2020-06-17 CA CA3140318A patent/CA3140318A1/en active Pending
- 2020-06-17 AU AU2020294879A patent/AU2020294879A1/en active Pending
- 2020-06-17 JP JP2021575275A patent/JP2022537338A/ja active Pending
- 2020-06-17 BR BR112021025462A patent/BR112021025462A2/pt unknown
- 2020-06-17 WO PCT/EP2020/066685 patent/WO2020254355A1/en unknown
- 2020-06-17 KR KR1020217041528A patent/KR20220010019A/ko unknown
- 2020-06-17 MX MX2021015538A patent/MX2021015538A/es unknown
-
2021
- 2021-12-13 IL IL288967A patent/IL288967A/en unknown
- 2021-12-16 US US17/553,523 patent/US20220169730A1/en active Pending
-
2024
- 2024-02-22 JP JP2024025419A patent/JP2024059798A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2024059798A (ja) | 2024-05-01 |
| CN114008081A (zh) | 2022-02-01 |
| CA3140318A1 (en) | 2020-12-24 |
| IL288967A (en) | 2022-02-01 |
| JP2022537338A (ja) | 2022-08-25 |
| US20220169730A1 (en) | 2022-06-02 |
| KR20220010019A (ko) | 2022-01-25 |
| BR112021025462A2 (pt) | 2022-02-01 |
| EP3986926A1 (en) | 2022-04-27 |
| WO2020254355A1 (en) | 2020-12-24 |
| AU2020294879A1 (en) | 2021-12-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20080001L (no) | Fremgangsmate til fremstilling av av 1,3-propanediol fra glycerol, et biprodukt fra fremstilling av biodiesel | |
| AR107902A2 (es) | Anticuerpos anti-cd37 | |
| NZ614857A (en) | Bispecific antibodies and methods for production thereof | |
| NZ592308A (en) | Non-human mammals for the production of chimeric antibodies | |
| NZ601171A (en) | Genetic engineering of non-human animals for the production of chimeric antibodies | |
| SG171577A1 (en) | Methods for producing yeast-based vaccines | |
| DE60116753D1 (de) | Humanisierte antikörper gegen den epidermalen wachstumsfaktorrezeptor | |
| MX2021015537A (es) | Metodo para la generacion de una celula que expresa anticuerpo biespecifico multivalente mediante la integracion diana de casetes de expresion multiples en una organizacion definida. | |
| MX2021015538A (es) | Metodo para la generacion de una celula que expresa un anticuerpo biespecifico bivalente mediante la integracion dirigida de multiples casetes de expresion en una organizacion definida. | |
| MX2021015540A (es) | Metodo para la generacion de una celula que expresa un anticuerpo trivalente mediante la integracion dirigida de multiples casetes de expresion en una organizacion definida. | |
| MX2021015648A (es) | Metodo para la generacion de una celula que expresa un anticuerpo multiespecifico multivalente mediante integracion dirigida de multiples casetes de expresion en una organizacion definida. | |
| RU2017127208A (ru) | Строение экспрессионного вектора, новые способы получения клеток-продуцентов и их применение для рекомбинантного получения полипептидов | |
| MX2010004007A (es) | Metodo para la produccion de un anticuerpo. | |
| WO2009111778A3 (en) | Lymph nodes as a site for regeneration | |
| DE60234787D1 (de) | Blakeslea trispora zur herstellung von lycopin in hoher ausbeute, in einem geeigneten medium in abwesenheit eines exogenen corotenogenese-hemmstoffes | |
| ES2168971B1 (es) | Procedimiento de produccion de beta-caroteno. | |
| DE60214127D1 (de) | Hybridomzelllinie g250 und deren verwendung zur herstellung monoklonaler antikörper | |
| WO2007095336A3 (en) | Production of hiv | |
| TW200604559A (en) | Optical resin lens and method for producing optical resin material | |
| TW200600006A (en) | Method for cultivating cordyceps militaris fruiting body | |
| MX2021009533A (es) | Composiciones y metodos para usar anticuerpos bispecificos para unirse al complemento y a un antigeno objetivo. | |
| EA200702350A1 (ru) | Анилиды тиазолкарбоновой кислоты | |
| ATE423841T1 (de) | Verwendung von glutaminfreien medium | |
| ATE359359T1 (de) | Myeloma zellkultur in einem transferrin-freien medium mit niedrigem eisengehalt | |
| DE60319210D1 (de) | Verfahren zur virusproduktion |